Ariceum Therapeutics

Ariceum Therapeutics is a clinical stage radiopharmaceutical company focused on developing innovative treatments for hard-to-treat cancers. The company is dedicated to creating more specific and effective radiopharmaceuticals to visualize and eradicate cancer with fewer side effects. Their lead product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. Ariceum is developing Satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours. They are also advancing ATT001, a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which is soon to enter a Phase 1 clinical study in recurrent glioblastoma patients.

Ariceum was founded in 2021 and is headquartered in Berlin with operations in Germany, Switzerland and Australia. Their mission is to become the go-to company for radiopharmaceuticals and their vision is to create a better future for cancer patients. The company has a strong team of experienced professionals and is supported by a syndicate of leading specialist investors. Ariceum has been actively expanding its pipeline and is committed to delivering novel targeted therapies for patients with severe and challenging cancers.

Ariceum Therapeutics is a private biotech company committed to developing novel targeted radiopharmaceuticals for the diagnosis and treatment of hard-to-treat cancers. Their mission is to become the go-to company for more specific and effective radiopharmaceuticals by developing better targeted drugs that eradicate cancer more efficiently with fewer side-effects, all while prioritizing patient needs and innovation. Their core values of innovation, scientific rigor, and understanding the needs of patients, doctors, and caregivers guide their efforts to create a better future for cancer patients.

Ariceum Therapeutics promotes a healthy and motivating work culture that values individual talent and collaboration. Their emphasis on scientific rigor, innovation, and understanding the needs of patients, doctors, and caregivers indicates a commitment to a work environment that is both challenging and rewarding.